Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human bone morphogenetic protein 6
- Development stage
- Unknown
- Lead developer
- Genera Research
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Implant, Topical
01
Overview
Recombinant human Bone Morphogenetic Protein 6 (rhBMP6) is a biologic therapeutic belonging to the TGF-β superfamily. It is primarily developed for its potent osteoinductive properties, stimulating the differentiation of mesenchymal stem cells into osteoblasts and chondrocytes to promote bone and cartilage repair. A notable formulation, rhBMP6/ABC (Autologous Blood Graft Substitute), utilizes an autologous blood coagulum as a carrier to avoid the complications associated with bovine collagen scaffolds used in earlier BMP products. It has been investigated in clinical trials for bone healing in high tibial osteotomy and is also being researched for its potential to restore epidermal barrier function in atopic eczema by increasing filaggrin expression.
- Other names
- BMP6BMP-6BMP 6Bone Morphogenetic Protein 6ABGSAutologous Blood Graft SubstituterhBMP6/ABC
02
Targets
HJV (Hemojuvelin)BMPR1BACVR1 (Activin receptor type I)ACVR2B (Activin receptor type IIB)BMPR1AACVR2A (Activin receptor type 2A)BMPR2 (Bone morphogenetic protein receptor type II)F2 (Thrombin)A2M (Alpha-2-macroglobulin)
Beyond the preview
Go deeper on recombinant human bone morphogenetic protein 6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human bone morphogenetic protein 6.